Duyag, Jay-ann P.
HRN: 21-82-42 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/20/2022
CEFUROXIME 500MG (TAB)
08/20/2022
08/27/2022
ORAL
500mg
BID
S/P NSVD With RMLE And Repair
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes